Aaron G.L. Fletcher - May 23, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Aaron Fletcher by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
May 23, 2022
Transactions value $
$711,700
Form type
4
Date filed
5/25/2022, 09:09 AM
Previous filing
May 17, 2022
Next filing
Jun 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Purchase $528K +150K +20.41% $3.52 885K May 23, 2022 See footnote F1, F2
transaction CUE Common Stock Purchase $184K +55K +6.21% $3.34 940K May 24, 2022 See footnote F2, F3
holding CUE Common Stock 165K May 23, 2022 Direct
holding CUE Common Stock 8.87K May 23, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.31 to $3.62. The price reported in Column 4 is a weighted average price.
F2 The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
F3 The reported shares were purchased in the open market in multiple transactions at prices ranging from $3.21 to $3.52. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Cue Biopharma, Inc., any stockholder of Cue Biopharma, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3).